🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

19 results for “obinutuzumab” Clear

  1. METHYLPREDNISOLONE , PREDNISONE , Gazyvaro 1,000 mg concentrate for solution for infusion., Obinutuzumab placebo, Myfenax 500 mg film-coated tablets, DIPHENHYDRAMINE , PARACETAMOL

    Roche Registration Limited

    Lupus Nephritis (LN)

    phase 3 small molecule active

    1 trial

  2. OBINUTUZUMAB, RITUXIMAB

    Pari Pharma GmbH

    Idiopathic nephrotic syndrome (INS)

    phase 3 small molecule active

    1 trial

  3. Obinutuzumab

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 3 mab terminated

    1 trial

  4. Obinutuzumab

    United Therapeutics Europe Ltd

    Non-Hodgkin's Lymphoma

    phase 3 small molecule completed

    1 trial

  5. PREDNISONE, DOXORUBICIN , BENDAMUSTINE , VINCRISTINE , VINCRISTINE, CYCLOPHOSPHAMIDE , OBINUTUZUMAB, RITUXIMAB, RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, BENDAMUSTINE, RITUXIMAB, PREDNISONE , RITUXIMAB, OBINUTUZUMAB

    Fondazione Telethon ETS

    Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  6. VENETOCLAX, VENETOCLAX, BENDAMUSTINE, ACALABRUTINIB, CYCLOPHOSPHAMIDE, OBINUTUZUMAB, VENETOCLAX, FLUDARABINE, RITUXIMAB

    Pharma Mar S.A.

    Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation

    phase 3 small molecule active

    1 trial

  7. An Open-Label, Multi-Center, Phase Ib/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin (Plus A Single Pretreatment Dose of Obinutuzumab) in Adult Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma

    Roche Registration Limited

    Relapsed/refractory (r/r) B-cell Non-Hodgkin’s Lymphoma (NHL)

    phase 2 other active

    1 trial

  8. Induction therapy of GP(Pomalidomide+Obinutuzumab）

    China SXT Pharmaceuticals

    Indolent Lymphoma

    phase 2 small molecule active

    1 trial

  9. Linperlisib combination with obinutuzumab

    First Tracks Biotherapeutics

    Lymphoma

    phase 2 small molecule active

    1 trial

  10. OBINUTUZUMAB, Zanubrutinib

    BeiGene Ireland Ltd

    Relapsed/Refractory Follicular Lymphoma

    phase 2 small molecule active

    1 trial

  11. Obinutuzumab

    China SXT Pharmaceuticals

    Marginal Zone Lymphoma

    phase 2 small molecule active

    1 trial

  12. Obinutuzumab

    Adaptive Biotechnologies Corp

    Mantle Cell Lymphoma

    phase 2 mab active

    1 trial

  13. Obinutuzumab

    First Tracks Biotherapeutics

    Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  14. Obinutuzumab Injection [Gazyva]

    China SXT Pharmaceuticals

    Immune Thrombocytopenia

    phase 2 small molecule active

    2 trials

  15. TOCILIZUMAB, OBINUTUZUMAB, GLOFITAMAB, GLOFITAMAB

    Fondazione Telethon ETS

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  16. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Subcutaneous Glofitamab following Obinutuzumab Pretreatment in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

    Roche Registration Limited

    Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

    phase 1 other active

    1 trial

  17. TGR-1202 + Obinutuzumab + Chlorambucil

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 1 small molecule completed

    1 trial

  18. Obinutuzumab

    First Tracks Biotherapeutics

    Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    small molecule active

    1 trial

  19. zanubrutinib, bendamustine, and obinutuzumab

    First Tracks Biotherapeutics

    Follicular Lymphoma

    small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources